Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease |
| |
Authors: | Ribeiro Ricardo Vasconcelos André Costa Sandra Pinto Daniela Morais Antonio Oliveira Jorge Lobo Francisco Lopes Carlos Medeiros Rui |
| |
Affiliation: | Molecular Oncology Unit, Instituto Português de Oncologia, Porto, Portugal. |
| |
Abstract: | BACKGROUND: Leptin has been consistently associated with angiogenesis and tumoral growth. A G/A single nucleotide polymorphism (SNP) at the -2548 site in leptin gene (LEP) is associated with overexpression of leptin (A-allele). METHODS: We evaluated DNA samples from 268 (536 alleles) unrelated individuals, 118 healthy controls (HCs) and 150 prostate cancer (PC) patients, for leptin gene (LEP) locus -2548 genotypes. RESULTS: We found an overrepresentation of the A-allele in PC patients and that there is a significantly higher risk for PC among A carriers (OR = 1.60; confidence interval (CI), 1.13-2.28, P = 0.008). Linear trend analysis showed that quantitative increase of A-allele presence was associated with significantly higher risk for PC (P = 0.003) in heterozygous (OR = 2.11; CI, 1.20-3.71) and homozygous (OR = 2.93; CI, 1.27-6.75) genotypes. Furthermore, the AA and AG genotypes represent significantly higher risk (OR = 4.67; CI, 1.69-12.88 and OR = 2.58; CI, 1.19-5.58, respectively) for advanced disease. CONCLUSIONS: According to our results we hypothesize that the polymorphism in LEP gene may be relevant to PC risk and progression, supporting the hypothesis for leptin involvement in cancer ethiopathogenesis. |
| |
Keywords: | leptin polymorphism prostate cancer advanced disease PCR cancer risk |
本文献已被 PubMed 等数据库收录! |
|